September 2, 2015
Recommended Topic Related To:

Lexiva

"Current prevention strategies have reduced the incidence of HIV worldwide, but that decline has slowed in recent years. We need new prevention strategies if we are to realize President Obama's goal of an AIDS-free generation. Targeting people who"...

Lexiva




Indications
Dosage
How Supplied

INDICATIONS

LEXIVA® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.

The following points should be considered when initiating therapy with LEXIVA plus ritonavir in protease inhibitor-experienced patients:

  • The protease inhibitor-experienced patient trial was not large enough to reach a definitive conclusion that LEXIVA plus ritonavir and lopinavir plus ritonavir are clinically equivalent [see Clinical Studies].
  • Once-daily administration of LEXIVA plus ritonavir is not recommended for adult protease inhibitor-experienced patients or any pediatric patients [see DOSAGE AND ADMINISTRATION, Clinical Studies].
  • Dosing of LEXIVA plus ritonavir is not recommended for protease inhibitor-experienced pediatric patients younger than 6 months [see CLINICAL PHARMACOLOGY].

DOSAGE AND ADMINISTRATION

LEXIVA tablets may be taken with or without food.

Adults should take LEXIVA oral suspension without food. Pediatric patients should take LEXIVA oral suspension with food [see CLINICAL PHARMACOLOGY]. If emesis occurs within 30 minutes after dosing, re-dosing of LEXIVA oral suspension should occur.

Higher-than-approved dose combinations of LEXIVA plus ritonavir are not recommended due to an increased risk of transaminase elevations [see OVERDOSAGE].

When LEXIVA is used in combination with ritonavir, prescribers should consult the full prescribing information for ritonavir.

Adults

Therapy-naive Adults
  • LEXIVA 1,400 mg twice daily (without ritonavir).
  • LEXIVA 1,400 mg once daily plus ritonavir 200 mg once daily.
  • LEXIVA 1,400 mg once daily plus ritonavir 100 mg once daily.
    • Dosing of LEXIVA 1,400 mg once daily plus ritonavir 100 mg once daily is supported by pharmacokinetic data [see CLINICAL PHARMACOLOGY].
  • LEXIVA 700 mg twice daily plus ritonavir 100 mg twice daily.
    • Dosing of LEXIVA 700 mg twice daily plus 100 mg ritonavir twice daily is supported by pharmacokinetic and safety data [see CLINICAL PHARMACOLOGY].
Protease Inhibitor-experienced Adults
  • LEXIVA 700 mg twice daily plus ritonavir 100 mg twice daily.

Pediatric Patients (Aged at Least 4 Weeks to 18 Years)

The recommended dosage of LEXIVA in patients aged at least 4 weeks to 18 years should be calculated based on body weight (kg) and should not exceed the recommended adult dose (Table 1).

Table 1: Twice-daily Dosage Regimens by Weight for Protease Inhibitor-na´ve Pediatric Patients (Aged 4 Weeks and Older) and for Protease Inhibitorexperienced Pediatric Patients (Aged 6 Months and Older) Using LEXIVA Oral Suspension with Concurrent Ritonavir

Weight Twice-daily Dosage Regimen
< 11 kg LEXIVA 45 mg/kg plus ritonavir 7 mg/kga
11 kg - < 15 kg LEXIVA 30 mg/kg plus ritonavir 3 mg/kga
15 kg - < 20 kg LEXIVA 23 mg/kg plus ritonavir 3 mg/kga
≥ 20 kg LEXIVA 18 mg/kg plus ritonavir 3 mg/kga
a When dosing with ritonavir, do not exceed the adult dose of LEXIVA 700 mg/ritonavir 100 mg twice-daily dose.

Alternatively, protease inhibitor-naive children aged 2 years and older can be administered LEXIVA (without ritonavir) 30 mg per kg twice daily.

LEXIVA should only be administered to infants born at 38 weeks gestation or greater and who have attained a post-natal age of 28 days.

For pediatric patients, pharmacokinetic and clinical data:

  • do not support once-daily dosing of LEXIVA alone or in combination with ritonavir [see Clinical Studies].
  • do not support administration of LEXIVA alone or in combination with ritonavir for protease inhibitor-experienced children younger than 6 months [see CLINICAL PHARMACOLOGY].
  • do not support twice-daily dosing of LEXIVA without ritonavir in pediatric patients younger than 2 years [see CLINICAL PHARMACOLOGY].
Other Dosing Considerations
  • When administered without ritonavir, the adult regimen of LEXIVA tablets 1,400 mg twice daily may be used for pediatric patients weighing at least 47 kg.
  • When administered in combination with ritonavir, LEXIVA tablets may be used for pediatric patients weighing at least 39 kg; ritonavir capsules may be used for pediatric patients weighing at least 33 kg.

Patients With Hepatic Impairment

See CLINICAL PHARMACOLOGY.

Mild Hepatic Impairment (Child-Pugh Score Ranging from 5 to 6)

LEXIVA should be used with caution at a reduced dosage of 700 mg twice daily without ritonavir (therapy-naive) or 700 mg twice daily plus ritonavir 100 mg once daily (therapy-na´ve or protease inhibitor-experienced).

Moderate Hepatic Impairment (Child-Pugh Score Ranging from 7 to 9)

LEXIVA should be used with caution at a reduced dosage of 700 mg twice daily without ritonavir (therapy-naive), or 450 mg twice daily plus ritonavir 100 mg once daily (therapy-na´ve or protease inhibitor-experienced).

Severe Hepatic Impairment (Child-Pugh Score Ranging from 10 to 15)

LEXIVA should be used with caution at a reduced dosage of 350 mg twice daily without ritonavir (therapy-naive) or 300 mg twice daily plus ritonavir 100 mg once daily (therapy-na´ve or protease inhibitor-experienced).

There are no data to support dosing recommendations for pediatric patients with hepatic impairment.

HOW SUPPLIED

Dosage Forms And Strengths

LEXIVA tablets, 700 mg, are pink, film-coated, capsule-shaped, biconvex tablets with “GX LL7” debossed on one face.

LEXIVA oral suspension, 50 mg per mL, is a white to off-white suspension that has a characteristic grape-bubblegum-peppermint flavor.

Storage And Handling

LEXIVA tablets, 700 mg, are pink, film-coated, capsule-shaped, biconvex tablets, with “GX LL7” debossed on one face.

Bottle of 60 with child-resistant closure (NDC 49702-207-18).

Store at controlled room temperature of 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature). Keep container tightly closed.

LEXIVA oral suspension, a white to off-white grape-bubblegum-peppermint-flavored suspension, contains 50 mg of fosamprenavir as fosamprenavir calcium equivalent to approximately 43 mg of amprenavir in each 1 mL.

Bottle of 225 mL with child-resistant closure (NDC 49702-208-53).

This product does not require reconstitution.

Store in refrigerator or at room temperature (5° to 30°C; 41° to 86°F). Shake vigorously before using. Do not freeze.

Manufactured for: ViiV Healthcare, Research Triangle Park, NC 27709. by: GlaxoSmithKline, Research Triangle Park, NC 27709, Vertex Pharmaceuticals Incorporated, Cambridge, MA 02139. Revised: July 2015

Last reviewed on RxList: 8/7/2015
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied

Lexiva - User Reviews

Lexiva User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Lexiva sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.